TRAVERE THERAPEUTICS, INC. Finite-Lived Intangible Asset, Expected Amortization, after Year Five
TRAVERE THERAPEUTICS, INC. (TVTX) had Finite-Lived Intangible Asset, Expected Amortization, after Year Five of $30.05 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive · last filed 2026-02-19
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $30.05M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $18.99M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $11.56M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $29.04M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, after Year Five |
|---|---|
| 2025-12-31 | $30.05M 10-K · filed 2026-02-19 |
| 2024-12-31 | $18.99M 10-K · filed 2025-02-21 |
| 2023-12-31 | $11.56M 10-K · filed 2024-02-20 |
| 2022-12-31 | $29.04M 10-K · filed 2023-02-23 |
| 2021-12-31 | $41.44M 10-K · filed 2022-02-24 |
| 2020-12-31 | $48.69M 10-K · filed 2021-03-01 |
| 2019-12-31 | $54.92M 10-K · filed 2020-02-24 |
| 2018-12-31 | $65.71M 10-K · filed 2019-02-26 |
| 2017-12-31 | $74.96M 10-K · filed 2018-07-06 |
| 2016-12-31 | $72.15M 10-K · filed 2017-03-01 |
| 2015-12-31 | $84.12M 10-K · filed 2016-02-26 |
| 2013-12-31 | $1.01M 10-K/A · filed 2015-07-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |